Max-Planck-Gesellschaft Zur F&#xf6;rderung Der Wissenschaften E. V.

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

Other

Ribozyme Pharmaceuticals, Incorporated

Deutsches Primatenzentrum

Fritz Eckstein

David Brian Olsen

Wolfgang A Pieken

Fritz Benseler

David M Williams

Hermona Soreq

Shlomo Seidman

Olaf Heidenreich

Olaf Heindenreich

John B Hobbs

Leonid Beigelman

Alon Friedman

Haim Zakut

Daniela Kaufer

Lambert Skoog

Gerhard Hunsmann

Paul A Heaton

Narendra K Vaish

Lars Thelander

Gunnar Bjursell

Heinz Hartmann

The present invention refers to an RNA molecule with catalytic activity comprising at least one modified nucleoside, wherein the hydroxy group at the 2'-position of the ribose sugar is replaced by a modifier group, selected from halo, sulfhydryl, azido, amino, monosubstituted amino and disubstituted amino groups, a process for the preparation of modified RNA molecules and the use of modified RNA molecules as therapeutic agents and biocatalysts.

Modified ribozymes

The present invention relates to nucleic acid molecules with new motifs having catalytic activity, methods of syntheses and uses thereof.

Nucleic acid catalysts with endonuclease activity

Nucleic acid molecules with new motifs having catalytic activity, methods of synthesis, and use thereof are also described.

A synthetic nuclease resistant antisense oligodeoxynucleotide (AS-ODN) capable of selectively modulating human acetylcholinesterase (AChE) production and a composition comprising at least one AS-ODN as an active ingredient. A nuclease resistant antisense targeted against the splice junction in the AChE mRNA post-splice message is disclosed. The synthetic nuclease resistant AS-ODNs are capable of selectively modulating human AChE production in the central nervous system or capable of selectively reducing human AChE deposition of the neuromuscular junction. The present invention also provides a method to restore balanced cholinergic signalling in the brain and spinal cord or reduce AChE in the neuromuscular junction in patients in need of such treatment by administering to a patient in need of such treatment a therapeutically effective amount of at least one of the synthetic nuclease resistant AS-ODN capable of selectively modulating human AChE production.

Synthetic antisense oligodeoxynucleotides targeted to human ache

A synthetic nuclease resistant antisense oligodeoxynucleotide (AS-OND) capable of selectively modulating human acetylcholinesterase production in the central nervous system is provided. In an embodiment the antisense oligodeoxynucleotide can be selected from

Synthetic antisense oligodeoxynucleotides targeted to AChE

Synthetic antisense oligodeoxynucleotides and pharmaceutical

The claimed invention is drawn to RNA molecules with catalytic activity comprising at least one modified nucleoside having a modifier group replacing the hydroxy group at the 2'-position of the ribose sugar where the modifier group is an halo, amino, mono- or disubstituted amino, or an azido group, and methods of use in vivo.

The present invention refers to an RNA molecule with catalytic activity comprising at least one modified nucleoside, wherein the hydroxy group at the 2'-position of the fibose sugar is replaced by a modifier group, selected from halo, sulfhydryl, azido, amino, monosubstituted amino, and disubstituted andno groups, a process for the preparation of modified KNA molecules and the use of modified KNA molecules as therapeutic agents and biocatalysts.

Modified ribozymls

A method of treating viral diseases in a human subject is disclosed. The method involves applying effective amounts of the compound: ##STR1## wherein X is an azido group, a methoxy radical or a fluorine atom and B is thymine, uracil, guanine, cytosine, purine or hypoxanthine if X is methoxy or fluorine, and B is guanine, purine or hypoxanthine if X is azido or a pharmaceutically acceptable salt thereof. Also disclosed are compositions and compounds useful in the method.

Method of treating viral infections in humans and compositions therefor

Compositions for inhibiting cell growth, particularly compositions for the reatment of virus infections, are provided comprising the nucleoside 2'-azido-2'-desoxycytidine.

Methods for the treatment of viral infections

2'-Substituted-D-ribofuranosyl purine compounds, especially 2'-azido-D-riuranosyl purine compounds, of the formula ##STR1## in which R.sub.1 is azide, amino, halogen or alkoxy, and

Growing community of inventors

Gottingen, Germany

Fritz Eckstein